WI-ROCKWELL-AUTOMATION
20.4.2021 09:32:07 CEST | Business Wire | Press release
Rockwell Automation, Inc. (NYSE: ROK), the world’s largest company dedicated to industrial automation and digital transformation, and Comau, a global leader in industrial automation and robot manufacturer, announced today that they are joining forces to give businesses worldwide vital tools to maximize manufacturing efficiencies through unified robot control solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210420005326/en/
“Industrial companies are looking for efficient ways to integrate robotics into their operations for process optimization and agility,” said Rockwell Automation Chairman and CEO Blake Moret. “Rockwell Automation’s collaboration with Comau will simplify programming and lifecycle management, accelerating time to value for our customers.”
Moret said this expansion of robotic applications is rooted in Rockwell’s broader strategy to help industrial companies save time and improve performance with unified robot control, ultimately providing long-term value for their business. The partnership is a collaborative development and selling model that offers the unified robot control product to both companies’ customers.
“Comau’s robotics and industrial automation expertise, as well as its reputation for high performance, reliability, and quality, combined with Rockwell Automation’s global capabilities and experience in automated material handling, food and beverage, household and personal care, and life sciences, gives customers the incremental value of an integrated robot solution,” said Comau CEO Paolo Carmassi. “Comau is eager to work with such an important partner that has a market-leading global footprint in all industries.”
Engineers will now be able to program their entire machine in one environment, including Comau robot arms directly controlled through Rockwell Automation’s Logix-based controllers. Rockwell Automation’s Studio 5000® automation system design software provides relief from the time-consuming and often difficult task of trying to coordinate traditionally separate machine control and robot systems to work together using two different software tools.
Machine builders, system integrators, and others will gain development and deployment efficiencies through the use of digital engineering tools like Rockwell’s Emulate3D digital twin software, which creates digital models of production lines, auto-generates machine control code, and has built-in capabilities for Comau robots.
The combined Rockwell and Comau solutions will also offer benefits beyond enhanced integration. For example, end users can use analytics and digital twin tools to gain deeper insights into machine performance and potential production optimization. They can also use safety and security solutions to reduce business risks.
Operators on the manufacturing floor who use Rockwell’s FactoryTalk® software suite will benefit from being able to see both line and robot control systems on a single interface. In-plant and remote technicians will only need to learn and maintain one architecture to monitor both systems. They can also leverage Rockwell’s augmented reality (AR) tools to improve lifecycle and service cycle maintenance.
Automazioni Industriali Capitanio, a recognized system integrator, designs, manufactures, and commissions automation systems for the metals industry and is an early adopter of the joint solution. Marco Capitanio, managing director of AIC, said the Rockwell-Comau collaboration allows the company to offer a seamless robot solution for customers, which he sees as a key advantage for a machine builder.
“We value the simple and flexible programming environment, complete access to robot supervision and diagnostic parameters, and the ability to leverage existing automation panels and standard control devices,” Capitanio said.
Rockwell products and technology that will be key to robotics integration include the following:
- Allen-Bradley ControlLogix® control systems
- Kinetix® 5700 servo drive platform
- Studio 5000® automation system design software
- FactoryTalk® View human machine interface (HMI) software
- FactoryTalk® InnovationSuite™, powered by PTC digital transformation software suite
- Emulate3D™ digital twin software
- PTC Vuforia AR tools for remote collaboration and information capture
Comau’s comprehensive robot range meets the needs of a wide variety of industries, from automotive to logistics, food and beverage, and packaging, just to name a few. It includes more than 40 different industrial robotic arms, with load capacities from 3 to 650 KG.
About Comau
Comau, a member of Stellantis, is a worldwide leader in delivering advanced industrial automation products, and systems. With over 45 years of experience and a strong presence within every major industrial country, Comau is helping manufacturers of all sizes in almost any industry experience higher quality, increased productivity, faster time-to-market, and lower overall costs. Headquartered in Turin, Italy, Comau has an international network of 7 innovation centers, 5 digital hubs, 8 manufacturing plants that span 14 countries and employ more than 9,000 people. For more information, visit www.comau.com .
About Rockwell Automation
Rockwell Automation, Inc. (NYSE: ROK), is a global leader in industrial automation and digital transformation. We connect the imaginations of people with the potential of technology to expand what is humanly possible, making the world more productive and more sustainable. Headquartered in Milwaukee, Wisconsin, Rockwell Automation employs approximately 23,500 problem solvers dedicated to our customers in more than 100 countries. To learn more about how we are bringing the Connected Enterprise to life across industrial enterprises, visit www.rockwellautomation.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210420005326/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom